← FDA DRUG APPROVALS

FDA ANDA · ANDA203966

NEBIVOLOL HYDROCHLORIDE

Sponsor: TORRENT

APPLICATION
ANDA203966
TYPE
ANDA
ORIGINAL APPROVAL
2018-03-02
LATEST ACTION
2023-10-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NEBIVOLOL HYDROCHLORIDEDiscontinued
NEBIVOLOL HYDROCHLORIDE EQ 20MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEDiscontinued
NEBIVOLOL HYDROCHLORIDE EQ 5MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEDiscontinued
NEBIVOLOL HYDROCHLORIDE EQ 10MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEDiscontinued
NEBIVOLOL HYDROCHLORIDE EQ 2.5MG BASE · TABLET · ORAL

Approval history

2023-10-30Labeling · Supplement 2 · standardAP
2018-03-02UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →